NCS-382
Sign in to saveNCS-382 is a moderately selective antagonist for the GHB receptor. It blocks the effects of GHB in animals and has both anti-sedative and anticonvulsant effects. It has been proposed as a treatment for GHB overdose in humans as well as the genetic metabolic disorder succinic semialdehyde dehydrogenase deficiency (SSADHD), but has never been developed for clinical use.
Research
109 papers- A review of pharmacology of NCS-382, a putative antagonist of gamma-hydroxybutyric acid (GHB) receptor.CNS drug reviews · 2004
- Exploring the NCS-382 Scaffold for CaMKIIα Modulation: Synthesis, Biochemical Pharmacology, and Biophysical Characterization of Ph-HTBA as a Novel High-Affinity Brain-Penetrant Stabilizer of the CaMKIIα Hub Domain.Journal of medicinal chemistry · 2022
- The γ-hydroxybutyric acid (GHB) analogue NCS-382 is a substrate for both monocarboxylate transporters subtypes 1 and 4.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2020
- Radiofluorinated Analogs of NCS-382 as Potential PET Tracers for Imaging the CaMKIIα Hub Domain.ACS chemical neuroscience · 2025
- Toxicologic/transport properties of NCS-382, a γ-hydroxybutyrate (GHB) receptor ligand, in neuronal and epithelial cells: Therapeutic implications for SSADH deficiency, a GABA metabolic disorder.Toxicology in vitro : an international journal published in association with BIBRA · 2018
via PubMed
Wikidata facts
- Mass
- 240.076239
Show 3 more facts
- isomeric SMILES
- C1CC2=CC=CC=C2C(/C(=C\C(=O)[O-])/C1)O.[Na+]
- chemical formula
- C₁₃H₁₃NaO₃
- canonical SMILES
- C1CC2=CC=CC=C2C(C(=CC(=O)[O-])C1)O.[Na+]
Sources (1)
via Wikidata · CC0
~1 min read
Article
1 sectionsContents
- References
NCS-382 is a moderately selective antagonist for the GHB receptor. It blocks the effects of GHB in animals and has both anti-sedative and anticonvulsant effects. It has been proposed as a treatment for GHB overdose in humans as well as the genetic metabolic disorder succinic semialdehyde dehydrogenase deficiency (SSADHD), but has never been developed for clinical use.
==References==